Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats

Journal of Cellular Biochemistry

Volumn 112, Issue 10, 2011, Pages 2902-2909

  Mai, Qi Guang ^a,b   Zhang, Zhong Min ^a,b   Xu, Song ^a,b   Lu, Ming ^a,b   Zhou, Rong Ping ^a,b   Zhao, Li ^b   Jia, Chun Hong ^b   Wen, Zhi Hua ^b   Jin, Da Di ^a,b   Bai, Xiao Chun ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

metformin; osetoporosis; osteoclast; osteoprotegerin; receptor activator of nuclear factor B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MESSENGER RNA; METFORMIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TIBIA; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; METFORMIN; MICE; OSTEOBLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; OVARIECTOMY; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKULL; TIBIA;

RATTUS;

EID: 80053186807     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23206     Document Type: Article

References (25)

1. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, Zeng WS, Cheng BL, Luo SQ,. 2005. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem 280: 17497-17506. (Pubitemid 41389222)
2. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y,. 2007. Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318: 977-980. (Pubitemid 350098994)
3. Bak EJ, Park HG, Kim M, Kim SW, Kim S, Choi SH, Cha JH, Yoo YJ,. 2010. The effect of metformin on alveolar bone in ligature-induced periodontitis in rats: A pilot study. J Periodontol 81: 412-419.
4. Barrett-Connor E, Holbrook TL,. 1992. Sex differences in osteoporosis in older adults with non-insulin-dependent diabetes mellitus. JAMA 268: 3333-3337.
5. Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L,. 2006. Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 536: 38-46.
6. Gao Y, Li Y, Xue J, Jia Y, Hu J,. 2010. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 635: 231-236.
7. Johnson ML,. 2004. The high bone mass family-The role of Wnt/Lrp5 signaling in the regulation of bone mass. J Musculoskelet Neuronal Interact 4: 135-138. (Pubitemid 38877763)
8. Kanazawa I,. 2009. Usefulness of metformin in diabetes-related bone disease. Clin Calcium 19: 1319-1325.
9. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T,. 2008. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375: 414-419.
10. Khazai NB, Beck GJ, Umpierrez GE,. 2009. Diabetes and fractures: An overshadowed association. Curr Opin Endocrinol Diabetes Obes 16: 435-445.
11. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM,. 1995. Bone loss and bone turnover in diabetes. Diabetes 44: 775-782.
12. Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, Lee KU, Kim GS, Kim SW, Koh JM,. 2010. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 47: 926-937.
13. McGee SL, Hargreaves M,. 2008. AMPK and transcriptional regulation. Front Biosci 13: 3022-3033. (Pubitemid 351589217)
14. Mundy GR,. 2002. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593. (Pubitemid 37328925)
15. Patel S, Hyer S, Tweed K, Kerry S, Allan K, Rodin A, Barron J,. 2008. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int 82: 87-91.
16. Rakel A, Sheehy O, Rahme E, LeLorier J,. 2008. Osteoporosis among patients with type 1 and type 2 diabetes. Diabetes Metab 34: 193-205.
17. Shah M, Kola B, Bataveljic A, Arnett TR, Viollet B, Saxon L, Korbonits M, Chenu C,. 2010. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 47: 309-319.
18. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ,. 1997. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89: 309-319. (Pubitemid 27199902)
19. Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K,. 2009. Low serum osteoprotegerin levels in normoalbuminuric type 1 diabetes mellitus. Acta Diabetol 47: 105-110.
20. Suzuki K, Sugimoto C, Takizawa M, Ishizuka S, Kikuyama M, Togawa H, Taguchi Y, Nosaka K, Seino Y, Ishida H,. 2000. Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res Clin Pract 48: 185-191. (Pubitemid 30232839)
21. Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, Sugimoto C, Seino Y, Nagamatsu S, Ishida H,. 2005. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: The preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract 68: 117-125. (Pubitemid 40602618)
22. Teitelbaum SL,. 2000. Bone resorption by osteoclasts. Science 289: 1504-1508.
23. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K,. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234: 137-142. (Pubitemid 27267548)
24. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T,. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-3602.
25. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE,. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174. (Pubitemid 32995375)